These products are being recalled due to superpotency or amounts of desmopressin higher than specified, which may represent a potential safety risk.

What do you need to do?

• Do not stop taking your medication without speaking with your doctor.  The U.S. Food and Drug Administration (FDA) recommends that patients continue taking their medication, as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment.
• Please call your doctor right away to obtain a new prescription for another appropriate medication. Your doctor will be able to prescribe another medication for you so you can continue treating your condition without interruption. 

To get more information or to report any adverse events or quality problems experienced with the use of this product, you can contact Amring Pharmaceuticals directly, or you can report to the FDA's MedWatch Program.

• Manufacturer Information:

Amring Pharmaceuticals:
844.AMRING1 (844.267.4641)
Email:  amring@icsconnect.com

• To report an adverse event to the FDA Med Watch Program:

Online: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda

Regular Mail or Fax: Download form https://www.fda.gov/safety/medical-product-safety-information/forms-reporting-fda mail or submit by fax to 800.FDA.0178

Affected NDCs:

 

Lot	Exp Date	NDC #
Desmopressin Acetate Nasal Spray 10 mcg/0.1 mL, 5 mL
N14695P	08/2020	69918-501-05
N14695S	08/2020	69918-501-05
N15627G	10/2020	69918-501-05
N15627GA	10/2020	69918-501-05
P10422A	01/2021	69918-501-05
P10422AA	01/2021	69918-501-05
P10430G	03/2021	69918-501-05
P11319M	01/2021	69918-501-05
P12969H	05/2021	69918-501-05
P12969IR	05/2021	69918-501-05
P13216G	05/2021	69918-501-05
P13216P	05/2021	69918-501-05
R11842A	03/2022	69918-501-05
R11842S	03/2022	69918-501-05
R12630A	05/2022	69918-501-05
R13071H	04/2022	69918-501-05